TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $40 million versus the consensus estimate of $39.49 million.

2024 Target BRIUMVI Guidance

BRIUMVI U.S. net product revenue target of approximately $220 million to $260 million for the full year 2024
Full year 2024 target operating expense of approximately $250 million

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.